Showing 1841-1850 of 2123 results for "".
- Elevidys Receives Expanded Indication for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/elevidys-receives-expanded-indication-for-dmd/2470516/The Food and Drug Administration (FDA) has broadened the approval for Elevidys (delandistrogene moxeparvovec-rokl; Sarepta Therapeutics, Cambridge, MA) as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) aged ≥4 years with a confirmed mutation in the DMD gene, granting
- Wakix Treatment for Excessive Daytime Sleepiness in Pediatric Patients with Narcolepsy Approvedhttps://practicalneurology.com/news/wakix-treatment-for-excessive-daytime-sleepiness-in-pediatric-patients-with-narcolepsy-approved/2470515/The Food and Drug Administration (FDA) has approved Harmony Biosciences’ supplemental New Drug Application (sNDA) for Wakix (pitolisant; Harmony Biosciences, Plymouth Meeting, PA) for the treatment of excessive daytime sleepiness (EDS) in pediatric patients (aged 6 to <18 years) with nar
- Potentially Synergistic Effect Identified in Treatment with OnabotulinumtoxinA + Qulipta as a Prophylactic Polytherapy for Chronic Migrainehttps://practicalneurology.com/news/potentially-synergistic-effect-identified-in-treatment-with-onabotulinumtoxina-qulipta-as-a-prophylactic-polytherapy-for-chronic-migraine/2470509/A majority of people with chronic migraine treated with onabotulinumtoxinA experienced a potentially synergistic effect when Qulipta (atogepant; Abbvie, North Chicago, IL) was added to their prophylactic regimen. The results of a single-site real-world observational study were presented at the 66
- Study Examines Efficacy of Zavzpret Nasal Spray Treatment in Black and African-American Patients with Migrainehttps://practicalneurology.com/news/study-examines-efficacy-of-zavzpret-nasal-spray-treatment-in-black-and-african-american-patients-with-migraine/2470508/For Black and African-American people with migraine, treatment with Zavzpret (zavegepant; Pfizer, New York, NY) nasal spray resulted in clinical efficacy outcomes similar to those found in the overall population. Results of pooled subgroup analyses based on data from 2 studies were presented at t
- Long-Term Vyepti Therapy Reduced Pain, Headache Frequency, & Disability in People with Chronic Migrainehttps://practicalneurology.com/news/long-term-vyepti-therapy-reduced-pain-headache-frequency-disability-in-people-with-chronic-migraine/2470503/Adults with chronic migraine who received intravenous (IV) treatment with Vyepti (eptinezumab-jjmr; Lundbeck, Deerfield, IL) at 300 mg every 12 weeks showed early reductions in migraine frequency, pain severity, and disability, which were sustained over 2 years. Results of a post-hoc analysis of
- 9 Leaders in Sleep Medicine & Research Honored at 2024 SLEEP Meetinghttps://practicalneurology.com/news/9-leaders-in-sleep-medicine-research-honored-at-2024-sleep-meeting/2470496/At the 2024 SLEEP meeting of the Associated Professional Sleep Societies in Houston, Texas, 9 awards were granted to leaders in sleep medicine and sleep research during the plenary session on Monday, June 3. These awards recognize individuals who have made singular contributions to the AASM
- Aimovig Safe and Effective in Patients with Episodic Migraine and Prior Treatment Failures According to OLE Study Resultshttps://practicalneurology.com/news/aimovig-safe-and-effective-in-patients-with-episodic-migraine-and-prior-treatment-failures-according-to-ole-study-results/2470462/Analysis of 3-year open-label extension (OLE) results assessing the long-term safety and efficacy of Aimovig (erenumab-aooe; Amgen, Dublin, Ireland/Novartis, East Hanover, NJ) in patients with episodic migraine (EM) demonstrated sustained improvement in the reduction of monthly migraine days (MMD
- CSF Biomarkers of Inflammation Are Predictive of Cognitive Declinehttps://practicalneurology.com/news/csf-biomarkers-of-inflammation-are-predictive-of-cognitive-decline/2470452/Analysis of study results presented at the American Academy of Neurology (AAN) 2024 Annual Meeting demonstrate that cerebrospinal fluid (CSF) inflammatory cytokine levels are predictive of clinically meaningful cognitive decline (CMCD) at 1 year follow up. TGF-β3 and TNFR2 were shown to be t
- UCSF Professor Bruce Ovbiagele, MD Recognized with Scientific Breakthrough Award at AAN 2024https://practicalneurology.com/news/ucsf-professor-bruce-ovbiagele-md-recognized-with-scientific-breakthrough-award-at-aan-2024/2470442/This year, the American Brain Foundation (ABF) awarded Bruce Ovbiagele, MD, MAS, FAAN the annual Scientific Breakthrough Award. Dr Ovbiagele, a Professor of Neurology at University of California (UC) San Francisco and Associate Dean of the San Francisco Veterans Affairs (VA) Healthcare Syste
- New Study Examines the Risk of Relapse in Those Discontinuing MS Therapyhttps://practicalneurology.com/news/new-study-examines-the-risk-of-relapse-in-those-discontinuing-ms-therapy/2470432/The discontinuation of high-efficacy therapies (HETs) that impact immune cell trafficking, including Tysabri (natalizumab; Biogen, Cambridge, MA) and Gilenya (fingolimod; Novartis, East Hanover, NJ), in people aged ≥50 years with nonactive multiple sclerosis (MS) was associated with a signific